이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Scorpius Holdings 관리

관리 기준 확인 4/4

Scorpius Holdings' CEO는 Jeff Wolf, Aug2008 에 임명되었습니다 의 임기는 15.83 년입니다. 총 연간 보상은 $ 575.00K, 100% 로 구성됩니다. 100% 급여 및 0% 보너스(회사 주식 및 옵션 포함). 는 $ 43.76K 가치에 해당하는 회사 주식의 1.11% 직접 소유합니다. 43.76K. 경영진과 이사회의 평균 재임 기간은 각각 4.8 년과 7.4 년입니다.

주요 정보

Jeff Wolf

최고 경영자

US$575.0k

총 보상

CEO 급여 비율	100.0%
CEO 임기	15.9yrs
CEO 소유권	0.02%
경영진 평균 재임 기간	4.8yrs
이사회 평균 재임 기간	7.5yrs

최근 관리 업데이트

Recent updates

Here's Why We're Watching Heat Biologics' (NASDAQ:HTBX) Cash Burn Situation

Dec 28

Here's Why We're Not Too Worried About Heat Biologics' (NASDAQ:HTBX) Cash Burn Situation

Sep 02

Reflecting on Heat Biologics' (NASDAQ:HTBX) Share Price Returns Over The Last Five Years

Mar 07

Here's Why We're Not Too Worried About Heat Biologics' (NASDAQ:HTBX) Cash Burn Situation

Jan 13

Heat Biologics signs a licensing agreement; Appoints new CFO

Jan 06

Heat Biologics soars 14% on completion of ZVX-60 vaccine cell line for COVID-19

Dec 16

Introducing Heat Biologics (NASDAQ:HTBX), The Stock That Zoomed 124% In The Last Year

Nov 20

Heat Biologics Provides Update, And Other News: The Good, Bad And Ugly Of Biopharma

Nov 02

CEO 보상 분석

Jeff Wolf 의 보수는 Scorpius Holdings 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Mar 31 2024	n/a	n/a	-US$32m
Dec 31 2023	US$575k	US$575k	-US$40m
Sep 30 2023	n/a	n/a	-US$53m
Jun 30 2023	n/a	n/a	-US$52m
Mar 31 2023	n/a	n/a	-US$45m
Dec 31 2022	US$3m	US$562k	-US$41m
Sep 30 2022	n/a	n/a	-US$38m
Jun 30 2022	n/a	n/a	-US$36m
Mar 31 2022	n/a	n/a	-US$36m
Dec 31 2021	US$6m	US$540k	-US$35m
Sep 30 2021	n/a	n/a	-US$28m
Jun 30 2021	n/a	n/a	-US$29m
Mar 31 2021	n/a	n/a	-US$27m
Dec 31 2020	US$6m	US$440k	-US$26m
Sep 30 2020	n/a	n/a	-US$23m
Jun 30 2020	n/a	n/a	-US$20m
Mar 31 2020	n/a	n/a	-US$21m
Dec 31 2019	US$3m	US$428k	-US$20m
Sep 30 2019	n/a	n/a	-US$22m
Jun 30 2019	n/a	n/a	-US$19m
Mar 31 2019	n/a	n/a	-US$18m
Dec 31 2018	US$1m	US$417k	-US$16m
Sep 30 2018	n/a	n/a	-US$14m
Jun 30 2018	n/a	n/a	-US$13m
Mar 31 2018	n/a	n/a	-US$12m
Dec 31 2017	US$964k	US$417k	-US$12m

보상 대 시장: Jeff 의 총 보상 ($USD 575.00K )은 US 시장에서 비슷한 규모의 회사의 평균 수준입니다( $USD 683.56K ).

보상과 수익: Jeff 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Jeff Wolf (61 yo)

15.9yrs

테뉴어

US$575,000

보상

Mr. Jeffrey Alan Wolf, also known as Jeff, J.D. founded Scorpius Holdings, Inc. (formerly known as NightHawk Biosciences, Inc.) (formerly known as Heat Biologics, Inc.) in August 2008 and has been Chairman...

리더십 팀

이름	위치	테뉴어	보상	소유권
Jeffrey Wolf	Founder	15.9yrs	US$575.00k	0.018% $ 177.5
William Ostrander	CFO, Controller & Secretary	4.8yrs	US$375.00k	0.00020% $ 1.9
Abby Sorensen	Senior Marketing & Sales Development Manager	no data	데이터 없음	데이터 없음
Justin Stebbing	Chief Medical Advisor and Member of Scientific & Clinical Advisory Board	no data	데이터 없음	데이터 없음
George Peoples	Chief Medical Advisor	7.3yrs	데이터 없음	데이터 없음
Ania Szymanska	Site Head of Quality	less than a year	데이터 없음	데이터 없음
Joe Payne	President & COO of Scorpius BioManufacturing	less than a year	데이터 없음	데이터 없음
Nicole Temple	Head of Program Management	no data	데이터 없음	데이터 없음

4.8yrs

평균 재임 기간

경험이 풍부한 관리: SCPX 의 관리팀은 경험 ( 4.8 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Jeffrey Wolf	Founder	15.9yrs	US$575.00k	0.018% $ 177.5
Justin Stebbing	Chief Medical Advisor and Member of Scientific & Clinical Advisory Board	no data	데이터 없음	데이터 없음
John K. Prendergast	Independent Lead Director	8.3yrs	US$301.00k	0.0012% $ 11.7
John Monahan	Independent Director	14.7yrs	US$81.50k	0% $ 0
Llew Keltner	Member of Scientific & Clinical Advisory Board	no data	데이터 없음	데이터 없음
Anthony Tolcher	Scientific Advisory Board Member	6.3yrs	데이터 없음	데이터 없음
Roger Cohen	Member of Scientific & Clinical Advisory Board	no data	데이터 없음	데이터 없음
Richard Myers	Chairman of BioThreat Advisory Board	2.2yrs	데이터 없음	데이터 없음
Gary Acton	Member of Scientific & Clinical Advisory Board	no data	데이터 없음	데이터 없음
Robert Negrin	Member of Scientific Advisory Board	6.8yrs	데이터 없음	데이터 없음
Edward Smith	Independent Director	13.7yrs	US$92.50k	0% $ 0
Robert Levy	Member of Scientific Advisory Board	6.8yrs	데이터 없음	데이터 없음

7.5yrs

평균 재임 기간

70yo

평균 연령

경험이 풍부한 이사회: SCPX 의 이사회는 경험(평균 재직 기간 7.4 년)으로 간주됩니다.

Scorpius Holdings 관리

관리 기준 확인 4/4

주요 정보

최근 관리 업데이트

Scorpius Holdings, Inc., Annual General Meeting, Jul 19, 2024

Scorpius Holdings, Inc., Annual General Meeting, Aug 02, 2024

Nighthawk Biosciences, Inc. Announces the Promotion of Joe Payne to President and Chief Operating Officer of Its Scorpius Biomanufacturing Subsidiary

NightHawk Biosciences, Inc. Announces Executive Appointments

NightHawk Biosciences, Inc., Annual General Meeting, Sep 27, 2023

NightHawk Biosciences, Inc., Annual General Meeting, Sep 15, 2022

Recent updates

Scorpius Holdings Set to Launch First Mammalian Cgmp Campaign At San Antonio Facility in the 2024 3Rd Quarter

Scorpius Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $12.5 million.

Scorpius Holdings, Inc Successfully Executes First cGMP Microbial Batches at San Antonio Facility

NYSE Determines to Commence Proceedings to Delist Scorpius Holdings' Common Stock from the NYSE American Due to Company No Longer Suitable for Listing Pursuant to Section 1003(f)(v) of the NYSE American Company Guide

Scorpius Holdings, Inc., Annual General Meeting, Jul 19, 2024

Scorpius Holdings, Inc., Annual General Meeting, Aug 02, 2024

Scorpius Holdings, Inc. Provides Non-Compliance Update

Scorpius Holdings, Inc. announced delayed 10-Q filing

Scorpius Holdings, Inc. has completed a Composite Units Offering in the amount of $6 million.

Scorpius Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $11.5 million.

Scorpius Holdings, Inc. announced that it expects to receive $0.75 million in funding from Elusys Holdings Inc.

Scorpius Holdings Regains Compliance with Section 1007 of the NYSE American Company Guide

Scorpius Holdings Announces Receipt of Filing Delinquency Notification

Scorpius Holdings, Inc. announced delayed annual 10-K filing

Scorpius Holdings, Inc. to Report Fiscal Year 2023 Results on Mar 28, 2024

Scorpius Holdings, Inc. Provides Earnings Guidance for the Fourth Quarter of 2023

Price target decreased by 9.1% to US$10.00

Nighthawk Biosciences, Inc. Announces the Promotion of Joe Payne to President and Chief Operating Officer of Its Scorpius Biomanufacturing Subsidiary

NightHawk Biosciences, Inc. Announces Executive Appointments

Jeffrey Wolf acquired Elusys Therapeutics, Inc. from NightHawk Biosciences, Inc. (NYSEAM:NHWK).

NightHawk Biosciences, Inc. has filed a Follow-on Equity Offering in the amount of $4.037193 million.

NightHawk Biosciences, Inc. announced that it expects to receive $2.25 million in funding

NightHawk Biosciences, Inc. has filed a Follow-on Equity Offering in the amount of $4.037193 million.

NightHawk Biosciences, Inc. has filed a Follow-on Equity Offering in the amount of $4.037193 million.

NightHawk Biosciences, Inc. announced delayed 10-Q filing

NightHawk Biosciences, Inc., Annual General Meeting, Sep 27, 2023

NightHawk Biosciences, Inc., Annual General Meeting, Sep 15, 2022

Richard Myers to Become Chairman of NightHawk's BioThreat Advisory Board

Heat Biologics to Voluntarily Withdraw the Listing of the Company’s Common Stock

Heat Biologics Announces New PTX-35 Preclinical Data in Organ Transplantation and Provides Update on HS-110

Here's Why We're Watching Heat Biologics' (NASDAQ:HTBX) Cash Burn Situation

Heat Biologics, Inc. (NasdaqCM:HTBX) executed a definitive merger agreement to acquire Elusys Therapeutics, Inc.

Heat Biologics Unveils RapidVax, A Novel Cellular Vaccine Platform Targeting Known and Unknown Emerging Biological Threats

Third quarter 2021 earnings released: US$0.30 loss per share (vs US$0.43 loss in 3Q 2020)

Here's Why We're Not Too Worried About Heat Biologics' (NASDAQ:HTBX) Cash Burn Situation

Heat Biologics Unveils Skunkworx Bio, New Drug Discovery Subsidiary

Price target decreased to US$21.83

Price target decreased to US$23.83

Second quarter 2021 earnings released: US$0.26 loss per share (vs US$0.35 loss in 2Q 2020)

Consensus forecasts updated

Heat Biologics to Showcase Favorable Survival Data of HS-110 in Previously Treated Non-Small Cell Lung Cancer Patients

Heat Biologics, Inc. Announces Promising Survival Data of HS-110 in Two Treatment Settings of Lung Cancer for Presentation at 2021 American Society of Clinical Oncology Annual Meeting

Independent Lead Director recently sold US$205k worth of stock

Consensus forecasts updated

Consensus revenue estimates fall to US$1.98m

Heat Biologics names Anthony Manning as chief scientific advisor

Price target decreased to US$24.67

First quarter 2021 earnings released: US$0.31 loss per share (vs US$0.77 loss in 1Q 2020)

Heat Biologics EPS misses by $0.01, misses on revenue

We're Hopeful That Heat Biologics (NASDAQ:HTBX) Will Use Its Cash Wisely

Full year 2020 earnings released: US$1.63 loss per share (vs US$4.21 loss in FY 2019)

Reflecting on Heat Biologics' (NASDAQ:HTBX) Share Price Returns Over The Last Five Years

Heat Biologics, Inc. Announces Positive Interim Survival Data from Ongoing HS-110 Phase 2 Non-Small Cell Lung Cancer Trial

Heat Biologics, Inc. Announces Publication of Additional Preclinical COVID-19 Vaccine Results

New 90-day high: US$8.76

Price target lowered to US$27.30

Here's Why We're Not Too Worried About Heat Biologics' (NASDAQ:HTBX) Cash Burn Situation

Heat Biologics, Inc. Announces the Promotion of William Ostrander to Chief Financial Officer

Heat Biologics signs a licensing agreement; Appoints new CFO

New 90-day low: US$5.28

Analysts update estimates

Heat Biologics soars 14% on completion of ZVX-60 vaccine cell line for COVID-19

New 90-day low: US$1.01

Introducing Heat Biologics (NASDAQ:HTBX), The Stock That Zoomed 124% In The Last Year

Jeff T. Hutchins Leave as A Chief Scientific and Operating Officer from Heat Biologics, Inc

Heat Biologics Provides Update, And Other News: The Good, Bad And Ugly Of Biopharma

CEO 보상 분석

CEO

테뉴어